PacBio to Report First Quarter 2022 Financial Results on May 4, 2022
Rhea-AI Summary
PacBio (NASDAQ: PACB) will host its first-quarter 2022 financial results conference call on May 4, 2022, at 5:00 pm Eastern Time. The call will be accessible via webcast on the company's website. PacBio specializes in long-read sequencing technology, enhancing genomic research through its innovative instruments. This technology enables comprehensive analysis of genomes, transcriptomes, and epigenomes, thus significantly contributing to various scientific fields including human biomedical research and microbiology.
Positive
- Innovative long-read sequencing technology enhances genomic research capabilities.
- Strong presence in global scientific community with thousands of peer-reviewed publications.
Negative
- None.
News Market Reaction – PACB
In the trading session that priced this news, PACB declined 4.85%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2022 financial results on Wednesday, May 4, 2022, at 5:00 pm Eastern Time.
The call will be webcast live and may be accessed at PacBio’s website at: https://investor.pacificbiosciences.com/.
Date: Wednesday, May 4, 2022
Time: 5:00pm ET (2:00pm PT)
Listen via Internet: https://investor.pacificbiosciences.com/
Toll-free: 866-652-5200
International: 412-317-6060
Replay: https://investor.pacificbiosciences.com
If using the dial-in option, please dial into the call five to ten minutes prior to start time using the appropriate number above and ask to join the “PacBio Q1 Earnings Call.”
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB), is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information, please visit www.pacb.com and follow @PacBio.
Contacts
Investors:
Todd Friedman
650.521.8450
ir@pacb.com
Media:
Lizelda Lopez
pr@pacb.com
